cytarabine and gsk-j4

cytarabine has been researched along with gsk-j4 in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bai, J; Chen, Z; Cheng, T; Li, Y; Sheng, M; Xing, W; Yang, FC; Zhang, M; Zhang, P; Zhou, Y	1

Other Studies

1 other study(ies) available for cytarabine and gsk-j4

Article	Year
Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia. Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:6 Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzazepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytarabine; Drug Synergism; Enzyme Inhibitors; Female; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrimidines; RNA, Messenger; Up-Regulation; Xenograft Model Antitumor Assays	2018

Article

Year

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.

Journal of cancer research and clinical oncology, 2018, Volume: 144, Issue:6

Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Benzazepines; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Proliferation; Cytarabine; Drug Synergism; Enzyme Inhibitors; Female; Histones; Humans; Jumonji Domain-Containing Histone Demethylases; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Molecular Targeted Therapy; Pyrimidines; RNA, Messenger; Up-Regulation; Xenograft Model Antitumor Assays

2018